UKAuthority: UK may lose access to verified medicines database. “Patients will be at risk from fake medicines if the UK leaves the EU without a deal because access to a new EU-wide database could be lost, pharmaceutical leaders have warned.”
STAT News: As social media ‘influencers,’ patients are getting a voice. And pharma is ready to pay up. “Anne Marie Ciccarella is not a doctor, though she spends a great deal of time with them. She’s not a researcher, though she routinely pores over scientific papers on cancer. And even though she spent most of her career at an accounting firm, she’s getting paid by drug companies for her opinions. Ciccarella is one of a growing number of people who have leveraged their experiences as patients and the loyal followings they’ve built on social media into a career, no matter how small their audience.”
The Daily Beast: Reps. Greg Walden and Kevin McCarthy Get Tons of Money From Big Pharma. “As voters prepare to go to the polls, they can use a new database, ‘Pharma Cash to Congress,’ tracking up to 10 years of pharmaceutical company contributions to any or all members of Congress, illuminating drugmakers’ efforts to influence legislation.”
MSN: “Pre$cription for Power” database exposes Big Pharma. “Pharmaceutical companies gave at least $116 million to patient advocacy groups in a single year, reveals a new database logging 12,000 donations from large publicly traded drugmakers to such organizations. Even as these patient groups grow in number and political influence, their funding and their relationships to drugmakers are little understood. Unlike payments to doctors and lobbying expenses, companies do not have to report payments to the groups.”
Boing Boing: FDAAA Trials Tracker: leaderboard for pharma companies that break FDA clinical trial rules. “The US government currently requires all trials to be registered on ClinicalTrials.gov when they start — trials that aren’t reported in at their commencement are not eligible for consideration during FDA evaluation; and since ClinicalTrials.gov is public, it should be possible for the public and watchdogs to discover whether pharma companies are reporting in on all their trials. That’s where FDAAA Trials Tracker comes in: it downloads an XML dump from ClinicalTrials.gov, analyzes it, and tracks which trials are due or overdue, as well as ‘whether they have reported results in accor- dance with the law; give performance statistics for each individual trial sponsor; and calculate potential fines that could have been levied by the FDA against sponsors.'”
Kaiser Health News: Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount. “Two federal investigations — one examining opioid sales, another about a multiple sclerosis drug whose price had soared to $34,000 a vial — were only part of the troubles Mallinckrodt faced as the year began…. This year, the company left the industry trade group Pharmaceutical Research and Manufacturers of America, or PhRMA, after the group threatened to kick out companies that did not spend enough on research. Mallinckrodt, however, has been increasing its spending in another area: It has been writing checks to politicians.” The data resources are embedded in the article.
Sydney Morning Herald: Drug companies spent $287 million in four years on ‘educational’ events for doctors. “The drug industry is spending $72 million a year ‘educating’ doctors, with one company splashing $750,000 on a weekend conference. A new database of pharmaceutical company-funded events created by Sydney University researchers shows 42 companies shelled out $286 million on 117,000 events for doctors and nurses over a four-year period. The average cost of an event was $2500.”